Free Trial

Abrdn Life Sciences Investors (HQL) News Today

$14.02
+0.26 (+1.89%)
(As of 11:38 AM ET)
Abrdn Life Sciences Investors logo with Finance background
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Buys $33,312.00 in Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 2,400 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was acquired at an average cost of $13.88 per share, with a total value of $33,312.00. Following the completion of the purchase, the insider now owns 3,407,612 shares of the company's stock, valued at $47,297,654.56. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Abrdn Life Sciences Investors logo with Finance background
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Purchases $133,041.84 in Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 9,704 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Monday, June 10th. The stock was bought at an average cost of $13.71 per share, for a total transaction of $133,041.84. Following the purchase, the insider now directly owns 3,403,173 shares in the company, valued at $46,657,501.83. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Abrdn Life Sciences Investors logo with Finance background
Insider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires 9,598 Shares of Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 9,598 shares of Abrdn Life Sciences Investors stock in a transaction on Thursday, June 6th. The shares were bought at an average price of $13.80 per share, for a total transaction of $132,452.40. Following the purchase, the insider now owns 3,389,706 shares of the company's stock, valued at $46,777,942.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Abrdn Life Sciences Investors logo with Finance background
Saba Capital Management, L.P. Buys 33,357 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 33,357 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were bought at an average cost of $13.50 per share, for a total transaction of $450,319.50. Following the completion of the transaction, the insider now directly owns 3,354,025 shares in the company, valued at approximately $45,279,337.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Abrdn Life Sciences Investors logo with Finance background
Short Interest in Abrdn Life Sciences Investors (NYSE:HQL) Rises By 26.0%
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 73,600 shares, an increase of 26.0% from the April 30th total of 58,400 shares. Based on an average trading volume of 83,200 shares, the short-interest ratio is currently 0.9 days.
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Buys 1,303 Shares
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 1,303 shares of the firm's stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $13.50 per share, with a total value of $17,590.50. Following the completion of the purchase, the insider now owns 3,251,883 shares in the company, valued at $43,900,420.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Abrdn Life Sciences Investors (NYSE:HQL) Raises Dividend to $0.48 Per Share
Abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Thursday, May 9th. Stockholders of record on Thursday, May 23rd will be paid a dividend of 0.48 per share on Friday, June 28th. This represents a $1.92 annualized dividend and a dividend yield of 13.62%. The ex-dividend date is Wednesday, May 22nd. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.39.
Abrdn Life Sciences Investors (NYSE:HQL) Shares Purchased by Cornerstone Advisors LLC
Cornerstone Advisors LLC raised its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 73.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 494,340 shares of the company's stock after purchasing an add
Saba Capital Management, L.P. Purchases 34,755 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 34,755 shares of the business's stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $14.19 per share, with a total value of $493,173.45. Following the completion of the purchase, the insider now directly owns 3,250,580 shares of the company's stock, valued at approximately $46,125,730.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Saba Capital Management, L.P. Purchases 57,862 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 57,862 shares of the stock in a transaction dated Friday, May 10th. The stock was acquired at an average price of $13.86 per share, for a total transaction of $801,967.32. Following the completion of the transaction, the insider now directly owns 3,215,825 shares of the company's stock, valued at $44,571,334.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Purchases 10,986 Shares
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 10,986 shares of the firm's stock in a transaction on Wednesday, May 8th. The stock was purchased at an average cost of $13.70 per share, for a total transaction of $150,508.20. Following the completion of the acquisition, the insider now owns 3,140,590 shares in the company, valued at $43,026,083. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Insider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires 10,713 Shares of Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 10,713 shares of Abrdn Life Sciences Investors stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $13.62 per share, with a total value of $145,911.06. Following the completion of the acquisition, the insider now directly owns 3,079,443 shares of the company's stock, valued at $41,942,013.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 26,274 Shares
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 26,274 shares of the business's stock in a transaction dated Thursday, May 2nd. The shares were bought at an average price of $13.46 per share, for a total transaction of $353,648.04. Following the completion of the acquisition, the insider now owns 3,068,730 shares in the company, valued at $41,305,105.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Insider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Purchases 16,573 Shares of Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 16,573 shares of the firm's stock in a transaction that occurred on Tuesday, April 30th. The shares were bought at an average price of $13.13 per share, with a total value of $217,603.49. Following the acquisition, the insider now directly owns 3,042,204 shares in the company, valued at $39,944,138.52. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 120,304 Shares
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 120,304 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were bought at an average price of $13.00 per share, with a total value of $1,563,952.00. Following the completion of the transaction, the insider now owns 3,025,602 shares in the company, valued at $39,332,826. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Buys 20,529 Shares
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 20,529 shares of the firm's stock in a transaction that occurred on Wednesday, April 24th. The stock was purchased at an average cost of $13.12 per share, with a total value of $269,340.48. Following the completion of the transaction, the insider now owns 2,807,724 shares in the company, valued at $36,837,338.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Wolverine Asset Management LLC Sells 114,766 Shares of Abrdn Life Sciences Investors (NYSE:HQL)
Wolverine Asset Management LLC decreased its holdings in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 35.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,392
Saba Capital Management, L.P. Buys 2,022 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 2,022 shares of the stock in a transaction dated Monday, April 22nd. The shares were bought at an average cost of $12.88 per share, for a total transaction of $26,043.36. Following the acquisition, the insider now owns 2,738,992 shares in the company, valued at approximately $35,278,216.96. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Saba Capital Management, L.P. Purchases 81,738 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 81,738 shares of the company's stock in a transaction on Thursday, April 18th. The shares were purchased at an average price of $12.80 per share, with a total value of $1,046,246.40. Following the completion of the purchase, the insider now directly owns 2,694,511 shares of the company's stock, valued at $34,489,740.80. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Abrdn Life Sciences Investors (NYSE:HQL) Shares Bought by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC lifted its position in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 30.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 454,154 shares of the company's stock afte
Raymond James Financial Services Advisors Inc. Has $1.76 Million Position in Abrdn Life Sciences Investors (NYSE:HQL)
Raymond James Financial Services Advisors Inc. grew its stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 183.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 131,077 shar
Abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Decrease in Short Interest
Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 56,000 shares, a decline of 58.0% from the February 14th total of 133,400 shares. Based on an average trading volume of 130,100 shares, the days-to-cover ratio is currently 0.4 days.
Clough Capital Partners L P Acquires New Stake in Abrdn Life Sciences Investors (NYSE:HQL)
Clough Capital Partners L P purchased a new stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 130,450 shares of the company's
Quantedge Capital Pte Ltd Has $1.18 Million Stock Position in Abrdn Life Sciences Investors (NYSE:HQL)
Quantedge Capital Pte Ltd grew its holdings in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 60.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 94,420 shares of the company's stock afte
Abrdn Life Sciences Investors (NYSE:HQL) Raises Dividend to $0.39 Per Share
Abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Friday, February 9th. Shareholders of record on Thursday, February 22nd will be given a dividend of 0.39 per share on Thursday, March 28th. This represents a $1.56 dividend on an annualized basis and a yield of 11.06%. The ex-dividend date of this dividend is Wednesday, February 21st. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.30.
Raymond James & Associates Sells 136,694 Shares of abrdn Life Sciences Investors (NYSE:HQL)
Raymond James & Associates reduced its stake in abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 83.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,771 shares of the company's stock after selling 136
abrdn Life Sciences Investors (NYSE:HQL) is Rpo LLC's 6th Largest Position
Rpo LLC increased its holdings in abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 75.7% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 327,042 shares of the company's stock after purchasing an additional 140,942 shares during
Get Abrdn Life Sciences Investors News Delivered to You Automatically

Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

HQL Media Mentions By Week

HQL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HQL
News Sentiment

0.67

0.96

Average
Finance
News Sentiment

HQL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HQL Articles
This Week

0

1

HQL Articles
Average Week

Get Abrdn Life Sciences Investors News Delivered to You Automatically

Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NYSE:HQL) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners